InsiderTrades

Form 4 for SPRY ARS Pharmaceuticals, Inc.

Accepted 2024-12-04 00:00:00 ET · period of report 2024-12-02 · accession 0001415889-24-028349 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-12-04 2024-12-02+ SPRY Karas Eric Chief Commercial Off S - Sale+OE $14.04 -10.0K 5,693 -64% -$140.4K
DM 2024-12-04 2024-12-02+ SPRY Karas Eric Chief Commercial Off M - OptEx $1.50 +10.0K 9,410 New +$15.0K
DM 2024-12-04 2024-12-02+ SPRY Karas Eric Chief Commercial Off M - OptEx $0.00 -10.0K 584.6K -2% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-12-04 S D 6,283 $14.00 5,693 D — —
2 Common Common Stock 2024-12-04 M A 6,283 $1.50 11,976 D — —
3 Common Common Stock 2024-12-02 S D 3,717 $14.11 5,693 D — — (F2) The weighted average sale price for the transaction reported was $14.1139, and the range of prices were between $14.00 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
4 Common Common Stock 2024-12-02 M A 3,717 $1.50 9,410 D — —
5 Derivative Stock Option (Right to Buy) 2024-12-02 M D 3,717 $0.00 590,871 D $1.50 · — to 2032-05-23 3,717 Common Stock (F3) Immediately exercisable.
6 Derivative Stock Option (Right to Buy) 2024-12-04 M D 6,283 $0.00 584,588 D $1.50 · — to 2032-05-23 6,283 Common Stock (F3) Immediately exercisable.